Results
1 -
10 of
15Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside, Heart Failure Translational In Vivo Models for Cardiovascular Diseases, New Approaches to Drug Discovery Novel Drugs in the Treatment of Hypertension, Interventional Therapies for Secondary and Essential Hypertension Diabetes und Nieren, Der Diabetologe Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis, Heart Failure Reviews Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drugu2013Drug Interaction Studies In Vitro and In Vivo, European Journal of Drug Metabolism and Pharmacokinetics Neuer Mineralokortikoidrezeptor-Antagonist senkt Albuminurie in Studienphase 2, Info Diabetologie A Review of the Key Clinical Trials of 2015: Results and Implications, Cardiology and Therapy Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?, Current Hypertension Reports Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?, Current Diabetes Reports